Experiencing a traumatic brain injury (TBI) is associated with an earlier age of Parkinson’s onset, but not with more severe disease-associated nerve cell loss or younger age of death, a study suggests. These findings, presented at the 2021 Alzheimer’s Association International Conference in Denver and online, suggest that…
Cognition Therapeutics has received a grant from the Michael J. Fox Foundation (MJFF) for Parkinson’s Research to support preclinical work into two potential sigma-2 receptor modulators for Parkinson’s disease. The Therapeutic Pipeline Program Grant award, whose amount and duration were not specified, will help to fund studies of these…
Cantabio Pharmaceuticals has been awarded a grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to develop a small molecule that can reduce the aggregation of a protein called tau. The research may have applications in treating Parkinson’s and other brain diseases. “We are proud…
A clinical trial in the U.S. is evaluating whether home visits from healthcare providers might improve the quality of life for people with advanced Parkinson’s disease and their caregivers. The trial’s protocol was detailed in the paper, “Longitudinal, Interdisciplinary Home Visits Versus Usual Care…
Measuring changes in the temperature of the hands after immersion in cold water could be useful in making an early diagnosis of Parkinson’s disease, a small study suggests. The study, “A Non-Invasive IR Sensor Technique to Differentiate Parkinson’s Disease from Other Neurological Disorders Using Autonomic Dysfunction…
In treating Parkinson’s symptoms that aren’t being adequately controlled by levodopa, monoamine oxidase type B (MAO-B) inhibitors are better than catechol-O-methyltransferase (COMT) inhibitors, according to patient-reported assessments in a clinical trial. The real-world study found no difference in effectiveness between MAO-B — like COMT, a dopamine reuptake inhibitor —…
Aerobic exercise stabilizes progression of motor symptoms and improves cognitive function in people with Parkinson’s disease, according to additional data from the Park-in-Shape clinical trial. Notably, these benefits were found to be associated with increased neuronal connectivity in brain areas controlling such functions and with reduced brain atrophy (shrinkage). These…
Early treatment with Gocovri (amantadine) may delay the onset of dyskinesia, the uncontrolled movements that are a common side effect of levodopa use, according to a new study. The study, “Amantadine Treatment and Delayed Onset of Levodopa-Induced Dyskinesia in Patients with Early Parkinson’s Disease” was published…
All through 2021, Parkinson’s News Today brought you coverage of cutting-edge science and developments in treatment related to Parkinson’s disease. Here are the top 10 most-read Parkinson’s news stories of the year. We look forward to continuing to cover news for the Parkinson’s community in 2022. No. 10 – “…
In a “world-first,” scientists in Australia report in detail what happens to the PINK1 protein when it is activated, helping to clear the “confusion” that has surrounded this support protein for cells that include dopamine-producing neurons. Since mutations in the PINK1 gene that codes for this protein are known to cause…
Get regular updates to your inbox.
